IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... P/A soft, vulvovaginal examination: bleeding present, hymen intact. Patient was investigated, her UPT was negative, Hb 7 gm%, B Positive, Ultrasound revealed bulky uterus with 8 x 4 cm hyperechoic area with increased AV channels within it. Endometrium was not separately made out as seen in fig 1. MR ...
... P/A soft, vulvovaginal examination: bleeding present, hymen intact. Patient was investigated, her UPT was negative, Hb 7 gm%, B Positive, Ultrasound revealed bulky uterus with 8 x 4 cm hyperechoic area with increased AV channels within it. Endometrium was not separately made out as seen in fig 1. MR ...
Endometriosis Hormone Rx
... one six-month study, mifepristone improved symptoms and reduced endometrial implants without causing menopausal side effects. Unfortunately, it is commonly known as the "abortion pill" because its antiprogestin effects can induce miscarriage, and so its use is limited. ...
... one six-month study, mifepristone improved symptoms and reduced endometrial implants without causing menopausal side effects. Unfortunately, it is commonly known as the "abortion pill" because its antiprogestin effects can induce miscarriage, and so its use is limited. ...
Reproductive Health Drugs
... trimester 2nd and 3rd trimester effects vary. May result in growth retardation, respiratory problems, infection, bleeding or congenital heart problems ...
... trimester 2nd and 3rd trimester effects vary. May result in growth retardation, respiratory problems, infection, bleeding or congenital heart problems ...
Drugs affecting reproductive system
... (1) Converting the uterine epithelium from the proliferative to the secretory phase (2) Inhibiting LH secretion and ovulation (3) Development of galactophore (乳管) (4) Thermoregulation: increasing body temperature (5) Metabolism: antagonizing aldosterone, inducing hepatic drug-metabolizing enzyme ...
... (1) Converting the uterine epithelium from the proliferative to the secretory phase (2) Inhibiting LH secretion and ovulation (3) Development of galactophore (乳管) (4) Thermoregulation: increasing body temperature (5) Metabolism: antagonizing aldosterone, inducing hepatic drug-metabolizing enzyme ...
170 KB
... Bromhexine may increase the concentration of concurrently administered antibiotics in bronchial secretions. No clinically relevant interactions with other medications have been reported. Statement on Usage During Pregnancy and Lactation Pregnancy There is no data on the use of bromhexine in pregnant ...
... Bromhexine may increase the concentration of concurrently administered antibiotics in bronchial secretions. No clinically relevant interactions with other medications have been reported. Statement on Usage During Pregnancy and Lactation Pregnancy There is no data on the use of bromhexine in pregnant ...
Estrogen-Based Hormone Replacement Therapy
... gold standard for menopause symptom treatment. The efficacy of this product, however, results from the sum of its components even though not all are fully characterized. For this reason, CEE is not reproducible in a generic form. It is important to note equivalent doses of estrogen when prescribing ...
... gold standard for menopause symptom treatment. The efficacy of this product, however, results from the sum of its components even though not all are fully characterized. For this reason, CEE is not reproducible in a generic form. It is important to note equivalent doses of estrogen when prescribing ...
8 Steroids
... The study showed that 99 percent of 187 participants experienced either a return to menses or became pregnant within 90 days after stopping the study drug. Investigators reported that four women became pregnant before returning to menses and two women reported a return to menses more than 90 days af ...
... The study showed that 99 percent of 187 participants experienced either a return to menses or became pregnant within 90 days after stopping the study drug. Investigators reported that four women became pregnant before returning to menses and two women reported a return to menses more than 90 days af ...
Steroids: Estrogen and Progestin
... •Unlike the ER receptor, which requires a phenolic ring for binding, the PR favors a non-phenolic ring structure •There is a single gene that encodes two isoforms of the progesterone receptor (PR): PR-A and PR-B •Since the ligand-binding domains of the two PR isoforms are identical, there is no diff ...
... •Unlike the ER receptor, which requires a phenolic ring for binding, the PR favors a non-phenolic ring structure •There is a single gene that encodes two isoforms of the progesterone receptor (PR): PR-A and PR-B •Since the ligand-binding domains of the two PR isoforms are identical, there is no diff ...
“Natural” Hormone Replacement Therapy
... endometrial cancer are equivocal. The limited literature available is based on animal studies and some epidemiological data.2 As a low potency agent, it is somewhat safer than other estrogens; however, continuous use in high doses may have stimulatory effects on breast and endometrial tissue.3 One c ...
... endometrial cancer are equivocal. The limited literature available is based on animal studies and some epidemiological data.2 As a low potency agent, it is somewhat safer than other estrogens; however, continuous use in high doses may have stimulatory effects on breast and endometrial tissue.3 One c ...
estrogens & androgens
... • USE: for infertility caused by anovulatory cycle such as those seen in patients with PCOS • Side effect: multiple pregnancies, ovarian enlargement ...
... • USE: for infertility caused by anovulatory cycle such as those seen in patients with PCOS • Side effect: multiple pregnancies, ovarian enlargement ...
Pharmacology—Hormonal Preparations II
... and bleeding will begin. Must be given during the first 7 weeks of pregnancy. It is 85% effective when given alone. It is 95% effective when given in combo with vaginal prostaglandin or oral Misoprostol ADRs include n/v/d, abdominal pain, vaginal bleeding requiring intervention (5%). There is fetal ...
... and bleeding will begin. Must be given during the first 7 weeks of pregnancy. It is 85% effective when given alone. It is 95% effective when given in combo with vaginal prostaglandin or oral Misoprostol ADRs include n/v/d, abdominal pain, vaginal bleeding requiring intervention (5%). There is fetal ...
estrogens and androgens
... • USE: for infertility caused by anovulatory cycle such as those seen in patients with PCOS • Side effect: multiple pregnancies, ovarian enlargement ...
... • USE: for infertility caused by anovulatory cycle such as those seen in patients with PCOS • Side effect: multiple pregnancies, ovarian enlargement ...
duphaston - Endometriosis SHE Trust UK
... It may be used in older women as a form of HRT (Hormone Replacement Therapy). ...
... It may be used in older women as a form of HRT (Hormone Replacement Therapy). ...
Steroid Hormones
... - Tablet of 0.18 mg of norgestimate and 35 mg of ethinyl estradiol for 7 days - Tablet of 0.215 mg of norgestrimate and 35 mg of ethinyl estradiol for 7 days - Tablet of 0.25 mg of norgestrimate and 35 mg of ethinyl estradiol for 7 days ...
... - Tablet of 0.18 mg of norgestimate and 35 mg of ethinyl estradiol for 7 days - Tablet of 0.215 mg of norgestrimate and 35 mg of ethinyl estradiol for 7 days - Tablet of 0.25 mg of norgestrimate and 35 mg of ethinyl estradiol for 7 days ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.